Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

por Bennett, Christina N, Tomlinson, Christine C, Michalowski, Aleksandra M, Chu, Isabel M, Luger, Dror, Mittereder, Lara R, Aprelikova, Olga, Shou, James, Piwinica-Worms, Helen, Caplen, Natasha J, Hollingshead, Melinda G, Green, Jeffrey E
Publicado 2012